Wolverine Stack

The Wolverine Stack pairs Body Protection Compound-157 (BPC-157) and TB-500 to create a dual-action peptide protocol targeting tissue repair and injury recovery. BPC-157 acts locally at injury sites, promoting new blood vessel formation and collagen-producing cell activity. TB-500 operates systemically, supporting cell migration and tissue repair across multiple structures simultaneously. Neither peptide is FDA-approved for human use. BPC-157 carries a specific FDA Category 2 classification that prohibits pharmacy compounding. Both peptides appear on WADA’s 2026 Prohibited List. The evidence base is primarily animal model data. No published clinical trial has tested this specific combination in humans.

Key Takeaways

• The Wolverine Stack combines BPC-157 (local repair) and TB-500 (systemic recovery) to address both focal and whole-body healing deficits in one protocol.
• No published randomized controlled trial has tested BPC-157 and TB-500 together. All combined-stack data is anecdotal.
• BPC-157 is FDA Category 2: it cannot be compounded by licensed pharmacies in the United States.
• Both peptides are banned by WADA under the 2026 Prohibited List (S2), including out-of-competition use. Competitive athletes in NFL, UFC, NBA, NHL, MLB, and NCAA programs face career consequences.
• Anecdotal recovery timelines range from 2–4 weeks for acute injuries to 8–12 weeks for post-surgical or chronic cases.

Before you start Peptide therapy protocols involving BPC-157 and TB-500 require physician evaluation before use. Because BPC-157 cannot be legally compounded in the US, sourcing quality is a primary safety consideration. Anyone with a personal or family history of cancer should discuss the theoretical angiogenesis risks with a licensed oncologist before considering this protocol.

How BPC-157 Works: Mechanisms, Target Tissues, and Evidence

BPC-157 is a synthetic 15-amino-acid peptide derived from a protein found in human gastric juice. Research in animal models shows it promotes tissue repair through three primary mechanisms: stimulating new blood vessel growth (angiogenesis), activating fibroblast migration, and upregulating nitric oxide (NO) production. A 2011 study published in the Journal of Applied Physiology (Chang et al., PMID 21030672) found BPC-157 accelerated tendon-to-bone healing in a rat model. This is the most-cited preclinical reference for its orthopedic repair claims.

Key takeaways: how BPC-157 works

• BPC-157 acts locally at the injury site, not systemically. This is the defining functional distinction from TB-500.
• Fibroblast activation drives collagen Type I and III production: the structural proteins in tendons and ligaments.
• BPC-157 upregulates nitric oxide in endothelial cells, increasing blood flow to oxygen-depleted injury sites. This is a secondary pathway distinct from the fibroblast mechanism.
• The gut and mucosal healing effects of BPC-157 are supported by separate animal model literature and operate through distinct mechanisms from the orthopedic repair pathway.
• PeptideRx rates the evidence for BPC-157 in tissue repair as Grade C.

The BPC-157 repair mechanism operates in a triplet chain. BPC-157 stimulates fibroblast migration. Fibroblasts deposit collagen at the injury site. New blood vessels (via NO-mediated angiogenesis) supply the tissue with oxygen and growth factors. A separate mechanism governs gut and mucosal healing: BPC-157 demonstrates cytoprotective and anti-inflammatory effects on mucosal tissue in rat models (Gjurasin et al., PMID 20026178). These are distinct applications with distinct evidence trails.

Subcutaneous injection near the injury site is the primary administration route in supervised clinic contexts. Oral BPC-157 capsules are commercially available, but animal data indicates inferior tissue penetration compared to injectable forms. The bioavailability tradeoff is significant for orthopedic applications where local tissue concentration matters.

Learn more about BPC-157’s mechanism and evidence base.

How TB-500 Works: Systemic Recovery via Thymosin Beta-4 Activity

TB-500 is a synthetic peptide fragment based on Thymosin Beta-4, a naturally occurring 43-amino-acid protein found in platelets, macrophages, and thymic tissue. Thymosin Beta-4 has a broad biological role in actin regulation. TB-500 is a shorter synthetic fragment engineered to replicate its actin-binding and cell migration-promoting properties in a more stable, accessible form.

TB-500 promotes tissue repair by binding to actin filaments in cells, facilitating cytoskeletal reorganization that enables cell migration to injury sites. This systemic distribution is TB-500’s defining characteristic. Where BPC-157 concentrates at a localized site, TB-500 circulates throughout the body, supporting repair across multiple tissue types simultaneously: muscles, tendons, ligaments, and blood vessels.

Animal model data and a human trial proxy (ClinicalTrials.gov NCT00832091, testing Thymosin Beta-4 in venous stasis ulcers) provide the closest available evidence for human-relevant TB-500 mechanisms. That trial demonstrated tissue repair signaling consistent with TB-500’s proposed mechanism. No published trial has tested TB-500 alone — or in combination with BPC-157 — specifically for orthopedic injury recovery in humans.

TB-500 also supports collagen architecture quality. Where BPC-157 increases collagen quantity via fibroblast activation, TB-500 appears to reduce fibrotic scarring, supporting more organized collagen fiber deposition. This distinction matters for functional recovery in tendons and ligaments.

PeptideRx rates the evidence for TB-500 in systemic tissue repair as Grade C.

Learn more about Thymosin Beta-4 and its relationship to TB-500.

Why BPC-157 and TB-500 are Used Together: The Rationale for Combining Them

The Wolverine Stack is built on a local/systemic division of labor. BPC-157 addresses the focal injury site. TB-500 addresses systemic repair deficits across multiple tissues at the same time. Neither peptide alone covers both functions.

Data gap: No published clinical trial has tested BPC-157 and TB-500 together. The combination rationale is mechanistically plausible from separate preclinical studies. It remains unvalidated in human or combined animal models. This is not a gray area in the evidence record.

The rationale behind the stack is that orthopedic injuries rarely affect a single isolated structure. A tendon tear often involves surrounding muscle tissue, connective tissue, and vascular supply. BPC-157 concentrates repair activity at the tendon itself. TB-500 supports the surrounding tissue architecture and reduces fibrotic compensation elsewhere. Anecdotal clinical reports from supervised peptide therapy practices describe the combination as producing faster functional recovery than either peptide alone, but no controlled data validates this comparison.

Mechanism comparison table: BPC-157 vs TB-500

Attribute	BPC-157	TB-500
Mechanism	Angiogenesis, fibroblast activation, NO production	Cell migration, actin-binding, cytoskeletal reorganization
Target tissue	Localized: tendons, ligaments, gut and mucosal	Systemic: muscles, tendons, ligaments, blood vessels
Distribution	Local (injury-site concentrated)	Systemic (circulates body-wide)
Primary pathway	Collagen synthesis via fibroblast stimulation	Collagen architecture improvement; anti-fibrotic
Evidence level	Animal Model (Grade C)	Animal Model + human proxy NCT00832091 (Grade C)
Administration	SubQ near injury site; oral (lower bioavailability)	SubQ or IM; systemic delivery preferred

Learn more about how BPC-157 and TB-500 compare individually.

Evidence tier matrix

Claim	Evidence Tier	Source/Notes
BPC-157 promotes tendon healing	Animal Model	Chang et al., PMID 21030672 (rat model)
BPC-157 promotes gut/mucosal healing	Animal Model	Gjurasin et al., PMID 20026178
TB-500 supports cell migration and tissue repair	Animal Model + Human Proxy	NCT00832091 (venous stasis ulcers)
Wolverine Stack combined synergy	Anecdotal only	No published RCT; supervised clinic reports
BPC-157 anecdotal dosing (250-500 mcg/day)	Anecdotal	Community protocols; no clinical trial validation
TB-500 anecdotal dosing (2-5 mg/week)	Anecdotal	Community protocols; no clinical trial validation
Cycling (4-8 weeks) reduces risk	Anecdotal/Precautionary	No tachyphylaxis data published

Wolverine Stack Protocols: Dosing, Administration, and Cycling

No FDA-approved dosing standard exists for BPC-157 or TB-500. The ranges below derive from anecdotal community protocols and preclinical dose-scaling estimates. They do not represent prescribing recommendations. Physician oversight is required before starting any protocol.

Dosing

BPC-157 anecdotal protocols use 250–500 mcg per day administered subcutaneously near the injured tissue. TB-500 protocols use 2–5 mg per week split across two injections, administered subcutaneously or intramuscularly for systemic effect. Both peptides require reconstitution from lyophilized powder with bacteriostatic water. Sterile technique (alcohol-swabbed injection site, single-use needles, proper storage of reconstituted peptide) is non-negotiable regardless of the delivery method.

Administration

BPC-157 injection near the injury site maximizes localized effect. The subcutaneous route (pinching skin near the injury) is most commonly reported in supervised clinic contexts. TB-500 is administered systemically; location near the injury is not necessary. A common protocol in supervised settings uses abdominal or thigh SubQ for TB-500. Oral BPC-157 is available, but the bioavailability data from rat models suggests significantly lower tissue penetration than injectable forms. This tradeoff is particularly relevant for orthopedic applications where local tissue concentration matters.

Cycling

Anecdotal protocols cycle the Wolverine Stack on a 4–8 week on / 4 week off schedule. The rationale is precautionary: no published data establishes receptor desensitization for either peptide, but cycling is used to limit cumulative exposure to compounds with incomplete long-term safety data. Chronic injuries and post-surgical cases typically run the longer end (8 weeks) before reassessment. No clinical cycling standard exists.

Complementary protocol elements

Physical therapy is not a substitute for structured rehabilitation in these case reports. The protocols are described as complementary, not standalone interventions. The anecdotal data consistently suggests peptide protocols produce better outcomes when integrated with structured rehabilitation. Collagen supplementation (10–15 g/day) and Vitamin C (500–1,000 mg/day) are commonly added as supportive elements based on collagen synthesis research, though these represent separate evidence trails.

For practitioners using advanced protocols, KPV (a tripeptide with anti-inflammatory properties) and GHK-Cu (a copper peptide that stimulates collagen production) are sometimes added to the Wolverine Stack as extended options. KPV is proposed as a complement for its reported anti-inflammatory signaling. GHK-Cu is proposed for its collagen remodeling activity. Neither combination has been tested in published research. Both remain anecdotal additions within supervised clinic contexts only.

Protocol reference table

Peptide	Dose Range	Frequency	Route	Cycle Length	Evidence Tier
BPC-157	250–500 mcg	Daily	SubQ near injury	4–8 weeks on / 4 weeks off	Anecdotal only
TB-500	2–5 mg	2x/week	SubQ or IM (systemic)	4–8 weeks on / 4 weeks off	Anecdotal only
BPC-157 (oral)	500 mcg–1 mg	Daily	Oral (capsule)	Same as injectable protocol	Anecdotal; lower bioavailability

Side Effects, Risks, and Safety Considerations

Key takeaways: safety

• Known side effects are mild and anecdotal in tier: injection site reactions, nausea at higher doses, and transient headache are the most reported.
• The theoretical cancer risk via angiogenesis overstimulation is not confirmed in human data, but it is a firm contraindication consideration for anyone with cancer history.
• Sourcing quality is a direct safety variable. BPC-157 sourced outside the licensed pharmacy system (which is the only available pathway, given Category 2 status) carries contamination and dosing accuracy risks.

Known and reported side effects (anecdotal evidence tier):

• Injection site reactions: redness, mild swelling, temporary soreness (most commonly reported)
• Nausea: reported with higher BPC-157 doses (above 500 mcg); typically transient
• Headache: reported intermittently; mechanism unclear
• Fatigue: reported during the first week of TB-500 protocols in some supervised clinic case reports

Theoretical risks (not confirmed in clinical data):

BPC-157 and TB-500 both promote angiogenesis. In healthy tissue, this supports repair. In individuals with existing or undetected cancer, stimulating blood vessel formation could theoretically support tumor vascularization. This concern appears in the peptide therapy literature but has not been confirmed in human case studies as a documented adverse event. The risk is theoretical, not demonstrated. It remains a firm contraindication consideration for anyone with a cancer history, active malignancy, or significant family history.

Sourcing and impurity risk:

BPC-157’s FDA Category 2 status means it cannot be obtained from licensed compounding pharmacies in the US. This matters for safety, not just legality. A certificate of analysis (COA) from an accredited third-party laboratory is the minimum verification standard for any peptide sourced outside the regulated pharmacy system. COA documentation should confirm peptide identity, purity percentage, and absence of common contaminants. Sourcing from suppliers who do not provide third-party COAs increases the risk of receiving an incorrectly dosed, adulterated, or contaminated product.

When to stop: Persistent nausea, significant injection site inflammation, fever, or any symptoms that worsen rather than resolve within 48–72 hours warrant stopping the protocol and consulting a physician immediately.

Legal Status: FDA Classification, WADA Ban, and What It Means for You

Key takeaways: legal status

• BPC-157 is FDA Category 2: licensed pharmacy compounding is not legal. There is no regulated US supply chain for BPC-157.
• Both peptides are WADA S2 banned: in-competition and out-of-competition. Possession as a research compound is separate from the anti-doping violation of use.
• Six major sports organizations enforce the ban: NFL (since 2022), UFC, NBA, NHL, MLB, and NCAA.

FDA Category 2 — BPC-157 compounding prohibition

BPC-157 was placed on FDA’s Category 2 bulk drug substance list under the agency’s revised 2020 compounding guidance. Category 2 classification means a substance cannot be compounded by 503A or 503B pharmacies. These are the licensed pharmacy channels that legally produce custom formulations for physician-supervised use. There is no legal licensed-pharmacy pathway for BPC-157 in the US. Access is limited to unregulated “research use only” channels or clinical trial participation.

TB-500 does not carry the same categorical classification, but it also has no FDA-approved indication. It is technically purchasable as a research compound, but it is not approved for human therapeutic use.

Quality sourcing in this context: Given the absence of a regulated supply chain for BPC-157, sourcing verification matters more than in typical compounded medication contexts. Request a third-party COA confirming peptide purity (minimum 98%), sequence verification, and endotoxin testing before use. Physician oversight of the sourcing decision is strongly recommended.

WADA 2026 Prohibited List

WADA’s 2026 Prohibited List classifies both BPC-157 and TB-500 under Section S2 (Peptide Hormones, Growth Factors, and Related Substances). The ban applies both in-competition and out-of-competition. Sport-specific enforcement applies in:

• NFL (banned since 2022)
• UFC
• NBA
• NHL
• MLB
• NCAA (all divisions)

Career consequences for a positive test are not limited to competition bans. They include potential contract implications, public disclosure, and multi-year ineligibility periods depending on the governing body. Legal possession of these peptides as research compounds is distinct from the anti-doping violation of use, which is governed independently by each sports organization’s anti-doping code.

Regulatory summary table

Compound	FDA Status	Compounding Legal?	WADA Status (2026)	Sports Banned In
BPC-157	Not approved; Category 2	No (503A and 503B prohibited)	S2 Banned (in and out of competition)	NFL, UFC, NBA, NHL, MLB, NCAA
TB-500	Not approved	No approved indication	S2 Banned (in and out of competition)	NFL, UFC, NBA, NHL, MLB, NCAA

Who Should Consider the Wolverine Stack and Who Shouldn’t

Candidate profiles most represented in supervised clinic case reports:

• Athletes recovering from acute tendon or ligament injuries
• Individuals with chronic tendinopathy unresponsive to standard conservative care
• Post-surgical recovery cases (orthopedic procedures on tendons, ligaments, or muscle tissue)
• Active adults with overuse injuries impeding rehabilitation progress
• Patients under physician supervision pursuing performance-optimization or recovery protocols

Firm contraindications:

Anyone with an active cancer diagnosis, personal history of cancer, or significant family history should not use BPC-157 or TB-500 without explicit discussion with a licensed oncologist. The angiogenesis-promoting mechanism of both peptides presents a theoretical but biologically plausible risk in this population. Autoimmune conditions also warrant careful physician evaluation: the immune-modulating effects of both peptides are not well-characterized in this population. Pregnancy, breastfeeding, and individuals on immunosuppressive medications are contraindicated based on the absence of safety data in these groups.

Medical evaluation is required regardless of Rx pathway. The absence of an FDA-approved prescription route does not remove the need for physician oversight. It increases it. Quality sourcing, dosing calibration, protocol duration, and contraindication screening all require clinical judgment that self-directed use cannot replace.

The Bottom Line

The Wolverine Stack offers a mechanistically coherent rationale: pairing a local-acting repair peptide (BPC-157) with a systemic-acting recovery peptide (TB-500) to cover both focal and whole-body healing. The individual peptide evidence is real but limited to animal models, and no published study has tested the combination directly. If you are considering this protocol, the most important steps are physician evaluation before starting, quality verification of any compound sourced outside the regulated pharmacy system, and integration with structured physical therapy rather than replacement of it. Given BPC-157’s FDA Category 2 status and both peptides’ WADA S2 ban, the regulatory and legal context is the first conversation to have with your physician.

Frequently Asked Questions

How long does the Wolverine Stack take to work?

Anecdotal reports from supervised clinic contexts describe initial improvement in acute injuries within 2–4 weeks. Moderate injuries typically show meaningful progress at 4–8 weeks. Chronic tendinopathies and post-surgical recovery cases generally require 8–12 weeks before meaningful functional improvement is reported. No clinical benchmarks exist. Individual response varies with injury severity, protocol adherence, and whether physical therapy is integrated.

Can you legally buy BPC-157 and TB-500 in the US?

Both peptides are sold as “research use only” compounds in the US. BPC-157’s FDA Category 2 classification means it cannot be obtained from a licensed compounding pharmacy. TB-500 lacks an approved indication but is not subject to the same specific compounding prohibition. Neither peptide is FDA-approved for human use. Competitive athletes should treat purchase and possession as a separate question from WADA compliance: the anti-doping ban governs use, regardless of how the compound was legally acquired.

What is the difference between BPC-157 and TB-500?

BPC-157 acts locally at an injury site, stimulating fibroblasts, angiogenesis, and collagen synthesis in the specific tissue where it is administered. TB-500 distributes systemically, promoting cell migration and tissue repair across multiple structures at once. They address different phases and locations of the healing cascade. BPC-157 targets the injury directly. TB-500 supports the broader tissue environment around it.

Do you need a prescription for the Wolverine Stack?

No FDA-approved prescription pathway exists for either BPC-157 or TB-500. BPC-157 cannot be prescribed through a licensed compounding pharmacy due to Category 2 prohibition. Access is through unregulated research compound channels. Despite the absence of an Rx pathway, physician oversight is strongly recommended. Contraindication screening, dosing calibration, and protocol monitoring require clinical judgment that self-directed use cannot replace.

Can athletes use the Wolverine Stack without violating anti-doping rules?

No. Both BPC-157 and TB-500 appear on WADA’s 2026 Prohibited List under Section S2. The ban applies in-competition and out-of-competition. Governing body bans include the NFL (since 2022), UFC, NBA, NHL, MLB, and NCAA. A positive test carries career consequences under each organization’s anti-doping code, independent of whether use was medically supervised.

What is the difference between TB-500 and Thymosin Beta-4?

Thymosin Beta-4 is a naturally occurring protein with 43 amino acids, found in platelets, macrophages, and thymic tissue. It plays a broad role in actin regulation and cell migration throughout the body. TB-500 is a synthetic peptide fragment that replicates the actin-binding domain of Thymosin Beta-4 in a shorter, more chemically stable form. TB-500 is more accessible and stable than the full-length endogenous protein, which is why it appears in experimental peptide therapy protocols rather than the native compound.

Considering peptide therapy? Speak with a licensed physician to evaluate your injury history and discuss whether a supervised protocol is appropriate for your specific goals.

References

1. Chang CH, et al. (2011). The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology, 110(3):774–780. PMID 21030672.
2. Gjurasin M, et al. (2010). Peptide therapy with pentadecapeptide BPC 157 in traumatic nerve injury. Regulatory Peptides, 163(1–3):51–57. PMID 20026178.
3. Treadwell T, et al. (2012). Clinical experience with thymosin beta 4 and its potential role in tissue repair and regeneration. Annals of the New York Academy of Sciences, 1270:74–80. NCT00832091 cross-reference.
4. WADA (2026). 2026 Prohibited List. Section S2: Peptide Hormones, Growth Factors, and Related Substances.
5. FDA (2020). Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act: Category 2 List.

Disclaimer: PeptideRx provides physician-reviewed educational content about peptide therapy. PeptideRx does not provide medical advice, diagnosis, or treatment. BPC-157 and TB-500 are not FDA-approved for human therapeutic use. All dosing information reflects published research protocols and community-reported anecdotal ranges, not prescribing recommendations. Consult a licensed healthcare provider before making any decisions about peptide therapy. Content medically reviewed April 2026. Evidence grading criteria are working definitions pending formal review.